In recent years, it was found that NLRP3 inflammation was involved in the progression of cystitis [21,22], therefore, targeting the TXNIP/NLRP3 signal axis may be an effective therapeutic target for treating ketamine-associated cystitis. Here, NLRP3 is linked to cystitis.